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Abstract
BACKGROUND: Neuromyelitis optica spectrum disorders (NMOSD) are rare, progressive inflammatory disorders 
of the central nervous system characterized by severe, immune-mediated demyelination targeting optic nerves 
and spinal cord. Prior establishment of diagnostic criteria, patients were often misdiagnosed which led to delayed/
inappropriate treatment and disability. Current practice involving immunotherapies is insufficient. Recent data are 
encouraging since the novel treatments allow effective prevention.
AIM: The primary objective was to evaluate the current situation to identify challenges and develop intervention that 
might improve the current state as secondary objectives.
METHODS: Standard questionnaire containing 22 questions was developed. Collected data were analyzed and 
descriptive report was created.
RESULTS: Current estimated prevalence is approximately 20 NMOSD patients; trend is unknown due unavailability 
of patient registry. Six neurologists from one health-care institution are responsible for the whole management. 
Despite physician’s insufficient experience, ~80% of them are willing to switch patients into innovative treatments 
once available. Aquaporin-4-IgG testing is not routinely available resulting in ~30% testing rate. Approximately 
80–90% of patients are on maintenance treatment with immunosuppressant, corticosteroids are used for acute 
relapse. Lack of novel innovative medications is evident.
CONCLUSION: Current NMOSD management is challenging with significant unmet needs. Highest priorities that 
might provide improvement are: APQ4-IgG testing availability, establishment of patient registry, and availability of 
novel treatments.
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Introduction
Over a century ago, the first clinical descriptions 
of neuromyelitis optica (NMO) spectrum disorders 
(NMOSD, previously known as Devic disease or NMO), 
were documented by Devic and Gault [1], [2]. NMOSD 
are inflammatory disorders of the central nervous system 
(CNS) characterized by severe, immune-mediated 
demyelination, and axonal damage predominantly 
targeting the optic nerves and spinal cord. It was 
previously believed that NMOSD and multiple sclerosis 
(MS) represented one disease entity, with variable 
phenotypes and expression. Recent evidence indicates 
that NMOSD is distinct from classic relapsing-remitting 
MS with respect to pathogenesis, imaging features, 
biomarkers, neuropathology, and treatment. Now, 
NMOSD is recognized as a distinct clinical entity based on 
unique immunologic features. The discovery of a disease-
specific serum NMO-IgG antibody that selectively binds 
aquaporin-4 (AQP4) has led to increased understanding 
of a diverse spectrum of disorders. In NMOSD, florid 
demyelination and inflammation involve multiple spinal 
cord segments and the optic nerves with associated 
axonal loss, perivascular lymphocytic infiltration, and 
vascular proliferation [3] whereby necrosis and cavitation 
typically involve both grey and white matter [4]. The 
pathophysiology of NMOSD is thought to be primarily 
mediated by the humoral immune system [3], [5], [6], [7]. 
Several lines of evidence support an autoimmune 
pathogenesis for NMOSD. The most important of these 
was the identification of a NMOSD disease-specific 
autoantibody, AQP4 autoantibody [8]. Serum AQP4 
autoantibody titers at the nadir of clinical attacks have 
been shown to correlate with the length of longitudinally 
extensive spinal cord lesions [9], [10]. In addition, serum 
anti-AQP4 titers have been shown in several studies 
to correlate with clinical disease activity, decline after 
immunosuppressive treatment, and remain low during 
remissions [9], [10], [11]. Additional data support the 
autoimmune pathogenesis since NMOSD is frequently 
associated with some systemic autoimmune diseases 
mediated by pathological antibodies; as hypothyroidism, 
pernicious anemia, ulcerative colitis, myasthenia gravis, 
and idiopathic thrombocytopenic purpura; and non-
organ-specific disorders such as lupus erythematosus 
(LE), antiphospholipid antibody syndrome, and Sjögren 
syndrome [12], [13], [14].
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NMOSD is a rare disorder. The 
prevalence in various studies ranges from 0.5 to 
10/100,000 [15], [16], [17], [18], [19], [20], [21] 
and recognized gender, ethnic, and geographic 
disparities [22], [23]. The incidence of NMOSD 
in women is up to 10 times higher than in 
men [24], [25], [26]. The median age of onset is 
32–41 years, but cases are described in children and 
older adults [11], [15], [24], [25], [26].
Hallmark of NMOSD includes acute attacks 
of transverse myelitis (often causing limb weakness, 
sensory loss, and bladder dysfunction) or optic 
neuritis (bilateral or rapidly sequential) leading 
to severe visual loss with a typically relapsing 
course [1], [2], [3], [24], [26], [27]. Attacks most often 
occur over days, with variable degrees of recovery over 
weeks to months [28]. CNS involvement beside that of 
the spinal cord and optic nerves is also recognized in 
NMOSD patients.
NMOSD must be distinguished from MS, 
which is the most common disorder likely to cause 
CNS demyelination. Furthermore, acute disseminated 
encephalomyelitis and other autoimmune diseases 
such as LE and Behçet disease may rarely have 
similar presentations. According to the Revised 2015 
Diagnostic Criteria for NMOSD, diagnosis is based on 
the presence of cardinal clinical characteristics, AQP4 
antibody status, and magnetic resonance imaging 
neuroimaging features [29].
The rationale of the treatment of acute and 
recurrent relapses in NMOSD is based on evidence that 
humoral autoimmunity plays a role in the pathogenesis 
and is driven by the high attack-related disability, 
poor prognosis, and overall high risk of mortality if left 
untreated [11], [30]. All suspected NMOSD patients 
should be treated for acute attacks with high-dose 
intravenous corticosteroids (methylprednisolone 1 g 
daily for 3–5 days). For patients with severe symptoms, 
whose are unresponsive to corticosteroids, the 
suggested rescue treatment is plasma exchange started 
quickly [11], [31], [32]. Due to devastating nature of the 
disease, long-term maintenance therapy should be 
started as soon as possible after the first attack, since 
attacks may be frequent and neurological disability can 
accumulate rapidly [31], [33]. There are no data for 
optimum duration of immunosuppressive maintenance 
therapy, but guidelines suggest continuing for 5 years to 
cover period with the highest relapse risk (2–3 years after 
presentation) [34]. At present, there are no approved 
medications for the acute or maintenance treatment 
of NMOSD. Current practice includes off-label use of 
immunotherapies for prevention or relapse treatment.
There is no randomized, controlled trials that 
would confirm effectiveness and tolerability of these off-
labeled treatments.
A number of potential NMOSD pharmacological 
therapeutic targets have been identified, including 
interleukin-6 (IL-6), B cells, and complement. At present, 
there are ongoing Phase III trials investigating satralizumab 
(IL-6 inhibitor), eculizumab (C5 inhibitor), inebilizumab 
(CD19 mAb), and RC 18 (B cell activating factor inhibitor).
The natural history of NMOSD is one of the 
stepwise deteriorations due to accumulating visual, 
motor, sensory, and bladder deficits from recurrent attacks 
(relapses) which worsen over days to a nadir and recover 
over several weeks to months with significant sequelae. 
The predictors of a worse prognosis include the number 
of relapses within the first 2 years, the severity of the first 
attack, older age at disease onset, and an association 
with AQP4 antibody status. The mortality rates are high 
in NMOSD (ranges from 25% to 50%), most frequently 
secondary to neurogenic respiratory failure, which occurs 
with extension of cervical lesions into the brainstem or 
from primary brainstem lesions [11]. Progress in the 
diagnosis, treatment, and care of NMOSD patients is 
expected to decrease the mortality rates.
The primary objective of our study was to 
evaluate and clarify the current situation in NMOSD, 
while the secondary objectives were to identify the 
challenges, unmet needs and develop a potential 
intervention with aim to improve the current state.
Methods
A standard questionnaire was developed and 
specifically designed for this work, in cooperation with 
neurologists with experience in this field with aim to 
ensure relevance and easy comprehension. The survey 
contained 22 questions, divided in five sections related to 
NMOSD prevalence, current physician awareness and 
knowledge, AQP4 antibody testing, current treatment 
approach, and funding mechanism. This observational 
survey was conducted by four local neurologists with 
experience in demyelinating diseases, at University Clinic 
of Neurology in Skopje, Republic of Macedonia, over a 
period of 1 month, from April to May 2019. Collected 
data were analyzed and final report was prepared which 
consisted descriptive answer for each question.
Results
A group of four neurologists with experience 
in the field of this area answered to all questions and 
results divided in five sections are as follows:
NMOSD incidence and prevalence
Due to unavailability of an official patient data 
registry in our country and regular patient’s visits, the 
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NMOSD incidence and prevalence are approximate. 
According to the clinics archives stored at the University 
Clinic of Neurology, the current estimated prevalence is 
approximately 20 patients. At present, there are patients 
in diagnostic procedure.
Physician awareness and knowledge/
experience
All required processes and management 
(diagnosis, prescription, treatment, and follow-up) of 
NMOSD patients are performed at the PHO University 
Clinic of Neurology, Skopje, which is the only public 
tertiary institution for diagnosis and treatment of 
demyelinating diseases. NMOSD market in our country 
is split between public and private, with significant 
predominance of public by 98%. Six neurologists are 
currently active in diagnosis and treatment working 
with NMOSD patients at University Clinic of Neurology. 
However, they are not fully dedicated only to NMOSD, 
they also cover other neurological areas, such as 
MS, myasthenia gravis, and epilepsy. Although the 
small number of NMOSD patients, the neurologists 
are aware and have sufficient knowledge about the 
disease nature. Their level of awareness about IL-6 as 
a new mechanism of action and experience with IL-6 in 
NMOSD treatment is very low. However, despite these 
knowledge gaps, around 80% of neurologists treating 
NMOSD patients in the country would be open to treat 
their patients (switch) innovative treatment options.
AQP4 antibody testing
At present, AQP4 antibody testing is not 
available in any public institution in the country. Hence, 
patient’s blood samples are sent to private laboratories, 
which in turn send them abroad, sometimes 
questioning the reliability of the results. This process is 
not regularly organized and it is costly and paid out of 
the pocket. These issues impact on AQP4 testing rate 
which currently is around 30% of all population with 
demyelinating diseases (e.g., NMOSD).
Treatment approach
At present, NMOSD treatment rate is 
approximately 80–90% of all diagnosed patients. 
Almost all patients (95%) are treated with 
immunosuppressant, most of them with azathioprine 
(only 5% with mycophenolate mofetil) as first-line 
maintenance treatment. High-dose intravenous 
methylprednisolone is used in treatment of acute 
attacks. Patients with severe symptoms, which failed to 
corticosteroid treatment, plasma exchange are offered/
treatment option. Other medications (e.g., rituximab, 
and tocilizumab) are not in clinical use due to 
off-label limitation, and eculizumab/satralizumab is 
still not registered in Republic of Macedonia. Despite, 
lack of various treatment options currently around 
80% of all NMOSD patients are on maintenance 
treatment with available immunosuppressant. Since 
immunosuppressive drugs are the only approved and 
available treatment option, physicians are not able 
to switch from 1 L into 2 L maintenance if needed. At 
present, there is no ongoing clinical trial in our center 
for investigating new treatment options. At the same 
time, physicians are experience since they participated 
in few multicentric clinical trials for MS or other 
neurological diseases.
Funding mechanism
Reimbursement and/or funding process 
of rare/orphan disease in our country is managed 
through a special funding mechanism organized and 
leads by the Ministry of Health. Ministry of Health is 
responsible for allocating funds for the treatment of 
rare diseases through a Rare Disease Program. To be 
funded, the medicine needs to proof certain level of 
evidence acceptable by the Ministry of Health as pricing 
strategy, business case model, and condition list/
process or similar. In this process, a dedicated patient 
association group (PAG) for rare diseases and alliance 
of PAGs for rare diseases have ability and capacity 
to shape the local healthcare policies, are able to 
influence in decision making process (approval and/or 
reimbursement). They have certain level of influence in 
the whole process throughout direct negotiation with the 
authorities, dissemination of information through social 
media, patient conference/meetings, etc. A dedicated 
PAG for NMOSD is not present yet.
Discussion
Despite latest improvements, significant unmet 
medical needs in the management of NMOSD are 
remaining. The current unmet needs can by divided in 
four sections: Knowledge (consistent and appropriate 
patient referral, appreciation of consequences of 
NMOSD relapses), diagnosis (further, robust validation, 
and adjustment of current NMOSD diagnostic criteria, 
AQP4-IgG-negative specific clinical, and neuroimaging 
features), maintenance treatment (robust evidence base 
for recommended drugs, approved drugs to treat NMOSD 
with a more favorable benefit/harm/risk balance), and 
improved symptom control (increased effectiveness in 
primary disease control to reduce secondary symptoms 
and disability, integrated multidisciplinary team 
approach for management to reduce/prevent relapses 
and disability) [35], [36], [37], [38], [39].
The whole management of NMOSD in republic 
of Macedonia, starting from diagnosis, treatment 
prescription until follow-up of patients, is done in the only 
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qualified center, PHO University Clinic for Neurology 
in Skopje. This center represents a public health-care 
institution at tertiary level with the low number (6) of 
neurologists dealing not exclusively with NMOSD. 
Recent published article, reported that 87% (13/15) of 
patients reported concern that their physicians’ were not 
knowledgeable about NMO and this had a potentially 
serious impact on outcomes [36]. Furthermore, patients 
believed that a delayed diagnosis was due to lack of 
knowledge of physicians at initial consultation and lack 
of patient support at early stages of diagnosis, and full 
consequences of the condition and relapses were not 
well communicated [36]. Taking this into account, we 
believe that appropriate tailored education will raise 
the level of knowledge that will help them to arise into 
local and/or regional NMOSD experts. Furthermore, 
improved local and regional habitat conservation plan 
coordination is needed to support patients with NMOSD 
and/or patient organization(s).
To make efficient clinical and policy decision-
making process at a national and institutional level, 
continuous examination of the disease trends in 
populations over time including incidence/prevalence 
rates and prognoses is critical. Recommendation from 
developed neurology centers in EU is that having 
an electronic patient data registry can support and 
overcome current situation. Their experience is showing 
that patient data registries can additionally support and 
enable a more effective use of limited resources; explore 
the impact of the disease and treatment on patients, 
including health-related quality; assess the clinical 
outcomes; support the health technology assessment 
process by providing data on the cost effectiveness of 
treatments, etc. Patient data registries are not new in 
our country, for example, registries for patients with rare, 
rheumatological, and endocrinological diseases are 
available. Nowadays, the University Clinic of Neurology 
is in process to establish (MS) registry. We believe that 
including the NMOSD patients in the upcoming MS 
patient registry in the future will be beneficial and serve 
as point for planning, delivery, and review of health care 
in our country. This will potentially provide us valuable 
data and insights in exact incidence, prevalence, 
disease trends and will support us in more efficient 
usage of health-care resources and will facilitate 
development of base for clinical investigations.
The importance of accurate ad early diagnosis 
of NMO is emphasized by Mutch et al. They concluded 
that the difficulty and delay in obtaining a diagnosis 
can lead to an accrual of disability if relapses are 
not treated quickly [36]. Prior establishing specific 
diagnostic criteria for NMOSD, patients were often 
misdiagnosed or diagnosis was delayed which led 
to inappropriate treatment and further disability 
progression. Now, AQP4-IgG testing is a core element 
of confirming the NMOSD diagnosis. However, in our 
center, AQP4-IgG testing is not available which resulted 
with significant proportion (70%) of suspected NMOSD 
patients not being AQP4-IgG tested. This diagnosis 
gap influences on early and accurate diagnosis and 
physician treatment decision-making process. We are 
convinced that establishment of central laboratory for 
AQP4-IgG testing in public sector will minimize the 
risk of misdiagnosis and will shorten the diagnosis 
period which will ultimately impact on the patients’ 
clinical outcomes. In addition, an action needs to be 
taken from the Macedonian neurology association to 
adopt and adapt locally the Revised Diagnostic Criteria 
for NMOSD, since without unified diagnostic criteria 
and adherence to them, a risk for misdiagnosis and 
inaccurate patient data registry will remain.
Until now, there are no curative treatments 
for NMOSD patients [31]. In addition, there is still no 
recommended treatment with satisfactory therapeutic 
efficacy and safety profile for NMOSD. At present, 
the foremost disease management priorities and 
treatment goal are prevention of attacks and reduction 
of the impact of NMOSD associated symptoms as 
long-term disease course stabilization [40]. Systemic 
immunosuppressive and chemotherapeutic agents are 
used off-label to reduce attack frequency and are the 
main first-line treatment options in our center. Systemic 
immunosuppression – corticosteroids and cytostatics 
are the most commonly used as first-line treatment 
to reduce attacks frequency. In addition, there are 
no approved medications for acute or maintenance 
treatment of NMOSD. In the past decade, significant 
progress has been made in NMOSD scientific research. 
At present, there are approximately 20 ongoing clinical 
trials that attract attention [41]. The ongoing Phase III 
trials are investigating emerging therapies for NMOSD 
prevention and include biologic agents targeting IL-6 
receptor blockade (satralizumab), B-cell depletion 
targeting CD19 (inebilizumab), complement C5 
cleavage inhibition (eculizumab), and B-cell activating 
factor inhibitor (RC 18). So far, our center was not 
included in any clinical trial that investigates the novel 
treatment options. We believe that participation in 
NMOSD clinical trial might impact on obtaining a more 
thorough understanding of the efficacy and safety of the 
investigational medicine and follow the standard routine 
diagnostic approach which will results in proper and 
accurate diagnosis. In addition, conducting a phase III 
clinical trial has many benefits but the biggest is the 
opportunity for patients to access new treatment in such 
rare disease where any current drug has not showed 
high efficacy and tolerability.
The latest investigations showed that a key 
driver of NMOSD pathophysiology is IL-6. It impacts 
on B-cell mediated features of NMOSD pathogenesis 
including AQP4 autoantibody production, blood–brain 
barrier permeability and granulocyte infiltration and 
complement activation [42], [43], [44], [45], [46]. The 
potential blockade of IL-6 receptor is thought to reduce 
IL-6 signaling and therefore reduces downstream 
inflammatory effect [43]. An emerging therapy that 
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targets IL-6R is satralizumab, which selectively 
inhibits the inflammatory effects of IL-6. Satralizumab 
was engineered to maximize suppression of IL-6 
signaling, minimize safety risks, and enable convenient 
dosing for patients with NMOSD. Satralizumab is a 
humanized monoclonal antibody with a long plasma 
circulation which is currently investigating in two pivotal 
clinical trials enrolling patients with NMO or NMOSD. 
SAkuraSky and SAkuraStar trials are evaluating the 
efficacy and safety of satralizumab administered by 
subcutaneous injection compared with placebo [47]. 
In addition, it is also being studied in pediatric patients 
as young as 12 years of age (SAkuraSky). Trials 
showed that satralizumab significantly reduced the 
risk of protocol-defined relapse and was well tolerated 
both in combination with immunosuppressants and 
as monotherapy. In June 2016, European Medicines 
Agency granted orphan drug designation and in 
December 2018, U.S. Food and Drug Administration 
(FDA) has granted breakthrough therapy designation 
to satralizumab for the treatment of NMO and NMOSD.
Eculizumab is a monoclonal antibody which 
administered by intravenous infusion binds to and 
inhibits the terminal complement component five and 
the membrane attack complex. In addition to NMOSD, 
it was investigated for the treatment of paroxysmal 
nocturnal hemoglobinuria, atypical hemolytic uremic 
syndrome, and generalized myasthenia gravis. 
Eculizumab was investigated among patients with 
AQP4-IgG-positive NMOSD in PREVENT clinical trial, 
which showed that those who received eculizumab 
had a significantly lower risk of relapse than those who 
received placebo and no significant between-group 
difference in measures of disability progression. In June 
2013, eculizumab received an orphan drug designation 
by the FDA, which provides incentives to assist and 
encourage the development of drugs for rare diseases.
The recent published data from clinical trials 
are encouraging since treatments showed consistently 
and effectively prevention of relapses, and reduction 
of other disease-associated symptoms. We endorse 
development and research of novel treatment options 
whose might fill the current significant unmet needs 
in the treatment of NMOSD patients and with the 
improvements in the diagnosis and care are expected 
to decrease the NMOSD mortality rates.
Conclusion
The analysis showed that the current situation 
in NMOSD setting in our country is challenging with 
many significant, yet unmet diagnostic and therapeutic 
needs. The highest priorities that will foster improvement 
of health care and quality of life of NMOSD patients are 
introduction of routine APQ4-IgG testing, establishment 
of patient registry according to adapted diagnostic and 
treatment recommendations and availability of novel 
emerging treatment options.
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